Search - tctmd.com

Displaying 1 - 20 of 69

Sort: Relevancy | Date

News Daily News

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

L.A. McKeown

July 24, 2025

News Daily News

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

L.A. McKeown

January 31, 2025

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

News Daily News

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes

Michael O'Riordan

August 19, 2024

News Daily News

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Yael L. Maxwell

August 16, 2024

News Daily News

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

Yael L. Maxwell

August 15, 2024

News Conference News AHA 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

Shelley Wood

November 11, 2023

News Daily News

SGLT2i May Be Helpful Early After Acute MI in Diabetic Patients

Todd Neale

July 17, 2023

News Daily News

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

Shelley Wood

May 30, 2023

News Features

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

L.A. McKeown

May 12, 2023

News Daily News

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

L.A. McKeown

April 19, 2023

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

Shelley Wood

August 22, 2022

News Daily News

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

Shelley Wood

July 25, 2022

News Conference News ESC Heart Failure 2022

Dapagliflozin Boosts Health Status Across LVEF Range

Shelley Wood

May 23, 2022

News Daily News

FDA Approves Empagliflozin for Treatment of HFpEF

Michael O'Riordan

February 24, 2022

News Daily News

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

Caitlin E. Cox

January 10, 2022

News Conference News ESC 2021

Finerenone Reduces CV Outcomes in Patients With Early CKD, Diabetes: FIGARO-DKD

Michael O'Riordan

August 28, 2021

News Daily News

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

Todd Neale

July 06, 2021

Advertisement

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

SGLT2i May Be Helpful Early After Acute MI in Diabetic Patients

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

What’s Going to Be Hot at ESC 2022?

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

Dapagliflozin Boosts Health Status Across LVEF Range

FDA Approves Empagliflozin for Treatment of HFpEF

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

Finerenone Reduces CV Outcomes in Patients With Early CKD, Diabetes: FIGARO-DKD

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content